Daiken Biomedical Co., Ltd. (TPE:7780)

Daiken Biomedical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	268.63	106.58	160.35	90.17
Depreciation & Amortization	6.4	4.21	0.92	0.1
Provision & Write-off of Bad Debts	0.89	0.88	0	0
Other Operating Activities	39.02	-23.94	2.25	19.36
Change in Accounts Receivable	-38.21	-26.19	-14.65	-2.51
Change in Inventory	-88.37	16.95	-84.29	-121.33
Change in Accounts Payable	71.11	25.36	15.6	34.09
Change in Unearned Revenue	0.71	-22.97	8.77	5.57
Change in Other Net Operating Assets	35.55	-29.12	16.24	16.12
Operating Cash Flow	295.74	51.75	105.21	41.58
Operating Cash Flow Growth	-	-50.81%	153.01%	-
Capital Expenditures	-0.59	-1.25	-	-
Sale (Purchase) of Intangibles	-3.7	-1.97	-	-0.05
Investment in Securities	-1,323	92.12	-61.41	-
Other Investing Activities	-8.44	-4.8	-0.56	-31.9
Investing Cash Flow	-1,336	84.09	-61.96	-31.95
Short-Term Debt Issued	-	470	183.83	33
Long-Term Debt Issued	-	-	65	127.36
Total Debt Issued	75	470	248.83	160.36
Short-Term Debt Repaid	-	-628	-58.83	-
Long-Term Debt Repaid	-	-121.24	-49.42	-24.36
Total Debt Repaid	-351.18	-749.24	-108.26	-24.36
Net Debt Issued (Repaid)	-276.18	-279.24	140.58	136
Issuance of Common Stock	4,313	1,000	-	-
Common Dividends Paid	-520.55	-3.08	-140.46	-
Financing Cash Flow	3,516	717.68	0.12	136
Foreign Exchange Rate Adjustments	-5.46	-0.86	-	-
Net Cash Flow	2,470	852.66	43.36	145.63
Free Cash Flow	295.15	50.5	105.21	41.58
Free Cash Flow Growth	-	-52.00%	153.01%	-
Free Cash Flow Margin	16.55%	3.71%	8.84%	4.70%
Free Cash Flow Per Share	4.80	1.15	4.68	2.67
Cash Interest Paid	1.14	6	3.36	1.18
Cash Income Tax Paid	26.48	56.96	32.74	-
Levered Free Cash Flow	208.62	171.51	15.47	-
Unlevered Free Cash Flow	209.33	175.26	17.57	-
Change in Working Capital	-19.2	-35.99	-58.33	-68.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.